Key result
Lp(a) testing occurs in only ~2% of ASCVD patients, rarely prompting lipid therapy changes.
Why the study?
What are the contemporary patterns of Lp(a) testing and its impact on lipid-lowering therapy management in patients with ASCVD?
Observational (n=1,948,540)
Yes
What are the contemporary patterns of Lp(a) testing and its impact on lipid-lowering therapy management in patients with ASCVD?
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Lp(a) testing is extremely low across the country, even in patients who have had established cardiovascular disease or established cardiovascular events. There are disparities in who is getting tested for Lp(a). Our study showed that patients of the Black race, older patients, those with high BMIs, and women are less likely to be tested than others.”
Lp(a) testing in US patients with ASCVD remains extremely low at 1.9%, and even when severely elevated, over half of patients do not receive intensification of lipid-lowering therapy, highlighting a major gap in guideline-directed care.
BACKGROUND: Although the effectiveness of Lp(a) (lipoprotein[a])–lowering therapies remains under study, lipid guidelines now recommend Lp(a) testing in all adults to identify individuals who need more aggressive risk factor modification. Therefore, we evaluate contemporary patterns of Lp(a) testing and the impact of testing on LDL-C (low-density lipoprotein cholesterol) management. METHODS: Electronic health record patient data from 13 US health systems from January 1, 2021 to January 1, 2025, were utilized to assess the annual proportion of patients with atherosclerotic cardiovascular disease who underwent Lp(a) testing. Multivariable logistic regression was used to identify factors associated with (1) Lp(a) testing and (2) high Lp(a) (≥125 nmol/L or ≥50 mg/dL). Changes in lipid-lowering therapy after Lp(a) testing were evaluated, stratified by Lp(a) level. RESULTS: Among 1 948 540 patients with atherosclerotic cardiovascular disease (44% female sex; mean age, 70.9±12.8 years), 36 410 (1.9%) had an Lp(a) test. Testing increased slightly over time but remained low: from 0.2% in 2021 to 0.8% in 2024. Among tested patients, 31.1% had elevated Lp(a). Although female sex (odds ratio, 0.95 [95% CI, 0.93–0.98]) and non-Hispanic Black patients (0.79 [95% CI, 0.76–0.82]) were less likely to undergo testing, these groups had higher odds of elevated Lp(a) (1.19 [95% CI, 1.14–1.25] and 2.83 [95% CI, 2.63–3.05], respectively). Intensification of lipid-lowering therapy in those with LDL-C≥55 mg/dL increased with higher Lp(a) levels: 32.7% with Lp(a) 125 to <200 nmol or 50 to <80 mg/dL, and 38.2% with Lp(a)≥200 nmol or ≥80 mg/dL had lipid-lowering therapy intensification ( P trend <0.001). CONCLUSIONS: Lp(a) testing remains low despite guideline recommendations. Although those with elevated Lp(a) were more likely to undergo lipid-lowering therapy intensification, over half of those with Lp(a)≥200 nmol/L or ≥ 80 mg/dL had no change in therapy. These results highlight a significant gap in clinical care and an opportunity to improve the use of Lp(a) testing to guide LDL-C management.
Shah et al. (2026) conducted an observational in Atherosclerotic cardiovascular disease (ASCVD) (n=1,948,540). Lp(a) testing vs. No Lp(a) testing was evaluated on Proportion of patients undergoing Lp(a) testing. Among 1.9 million patients with ASCVD, only 1.9% underwent Lp(a) testing, and over half of those with Lp(a) ≥200 nmol/L or ≥/dL had no change in lipid-lowering therapy.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: